Affimers: a novel biotherapeutic platform for the treatment of cancer

Affimers：一种治疗癌症的新型生物治疗平台

• 批准号: 710484
• 金额: $ 12.69万
• 依托单位: AVACTA LIFE SCIENCES LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Proof of Concept
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=710484
• 关键词: Affimers; novel; biotherapeutic; platform; treatment

Promexus is a new biotechnology company which will be developing a novel humantherapeutic protein (the Affimer) that will address some of the shortcomings of the currentantibody based drugs. Antibodies have been very successful at treating a wide range of humandisease such as asthma, arthritis and cancer, but they are expensive to produce and because oftheir large size can only be given via an injection. Affimers should be cheaper to make andbecause they are smaller and stable, can be administered topically (for example to the skin asa cream or to the lungs using an inhaler). Our first drug will be for the treatment of cancerwhere there is a need for cheaper more effective drugs. Affimers have all the properties topotentially make the next generation of therapeutics to meet the demand of new medicines

Promexus是一家新的生物技术公司，它将开发一种新的人类治疗蛋白质（Affimer），以解决目前基于抗体的药物的一些缺点。抗体在治疗哮喘、关节炎和癌症等多种人类疾病方面非常成功，但它们的生产成本很高，而且由于它们的体积很大，只能通过注射给药。亲和剂的制造成本应该更低，因为它们更小，更稳定，可以局部给药（例如，皮肤阿萨乳膏或肺部的吸入器）。我们的第一个药物将用于治疗癌症，那里需要更便宜更有效的药物。赋形剂具有所有的特性，有可能使下一代的治疗，以满足新的药物的需求，